Programme in Health Services & Systems Research, Duke-NUS Medical School, Singapore; Duke Global Health Institute, Duke University, Durham, NC, USA.
Programme in Health Services & Systems Research, Duke-NUS Medical School, Singapore.
Lancet Glob Health. 2021 May;9(5):e660-e667. doi: 10.1016/S2214-109X(21)00033-4. Epub 2021 Mar 19.
BACKGROUND: COBRA-BPS (Control of Blood Pressure and Risk Attenuation-Bangladesh, Pakistan, Sri Lanka), a multi-component hypertension management programme that is led by community health workers, has been shown to be efficacious at reducing systolic blood pressure in rural communities in Bangladesh, Pakistan, and Sri Lanka. In this study, we aimed to assess the budget required to scale up the programme and the incremental cost-effectiveness ratios. METHODS: In a cluster-randomised trial of COBRA-BPS, individuals aged 40 years or older with hypertension who lived in 30 rural communities in Bangladesh, Pakistan, and Sri Lanka were deemed eligible for inclusion. Costs were quantified prospectively at baseline and during 2 years of the trial. All costs, including labour, rental, materials and supplies, and contracted services were recorded, stratified by programme activity. Incremental costs of scaling up COBRA-BPS to all eligible adults in areas covered by community health workers were estimated from the health ministry (public payer) perspective. FINDINGS: Between April 1, 2016, and Feb 28, 2017, 11 510 individuals were screened and 2645 were enrolled and included in the study. Participants were examined between May 8, 2016, and March 31, 2019. The first-year per-participant costs for COBRA-BPS were US$10·65 for Bangladesh, $10·25 for Pakistan, and $6·42 for Sri Lanka. Per-capita costs were $0·63 for Bangladesh, $0·29 for Pakistan, and $1·03 for Sri Lanka. Incremental cost-effectiveness ratios were $3430 for Bangladesh, $2270 for Pakistan, and $4080 for Sri Lanka, per cardiovascular disability-adjusted life year averted, which showed COBRA-BPS to be cost-effective in all three countries relative to the WHO-CHOICE threshold of three times gross domestic product per capita in each country. Using this threshold, the cost-effectiveness acceptability curves predicted that the probability of COBRA-BPS being cost-effective is 79·3% in Bangladesh, 85·2% in Pakistan, and 99·8% in Sri Lanka. INTERPRETATION: The low cost of scale-up and the cost-effectiveness of COBRA-BPS suggest that this programme is a viable strategy for responding to the growing cardiovascular disease epidemic in rural communities in low-income and middle-income countries where community health workers are present, and that it should qualify as a priority intervention across rural settings in south Asia and in other countries with similar demographics and health systems to those examined in this study. FUNDING: The UK Department of Health and Social Care, the UK Department for International Development, the Global Challenges Research Fund, the UK Medical Research Council, Wellcome Trust.
背景:COBRA-BPS(孟加拉国、巴基斯坦、斯里兰卡的血压控制和风险降低计划)是一项多组分高血压管理项目,由社区卫生工作者主导,已被证明能有效降低孟加拉国、巴基斯坦和斯里兰卡农村社区的收缩压。在这项研究中,我们旨在评估扩大该项目所需的预算和增量成本效益比。
方法:在 COBRA-BPS 的一项群组随机试验中,年龄在 40 岁及以上、患有高血压、居住在孟加拉国、巴基斯坦和斯里兰卡 30 个农村社区的个体被认为有资格入组。在基线和试验的 2 年期间,前瞻性地量化了成本。所有成本,包括劳动力、租金、材料和用品以及签约服务,均按项目活动进行分层记录。从卫生部(公共支付方)的角度估计了将 COBRA-BPS 扩大到社区卫生工作者覆盖地区所有符合条件的成年人的增量成本。
结果:2016 年 4 月 1 日至 2017 年 2 月 28 日,对 11510 人进行了筛查,有 2645 人入组并纳入研究。参与者于 2016 年 5 月 8 日至 2019 年 3 月 31 日接受检查。COBRA-BPS 的第一年每位参与者的成本为孟加拉国 10.65 美元,巴基斯坦 10.25 美元,斯里兰卡 6.42 美元。人均成本为孟加拉国 0.63 美元,巴基斯坦 0.29 美元,斯里兰卡 1.03 美元。孟加拉国、巴基斯坦和斯里兰卡的每避免一个心血管残疾调整生命年的增量成本效益比分别为 3430 美元、2270 美元和 4080 美元,表明 COBRA-BPS 在这三个国家相对于每个国家世卫组织 CHOICE 阈值(人均国内生产总值的三倍)都是具有成本效益的。使用该阈值,成本效益可接受性曲线预测 COBRA-BPS 在孟加拉国的成本效益概率为 79.3%,在巴基斯坦为 85.2%,在斯里兰卡为 99.8%。
解释:COBRA-BPS 的低扩展成本和成本效益表明,对于在存在社区卫生工作者的低收入和中等收入国家的农村社区中日益严重的心血管疾病流行,该方案是一种可行的应对策略,并且应该符合南亚农村地区和其他具有类似人口统计学和卫生系统的国家的优先干预措施,这些国家都在本研究的审查范围内。
资金来源:英国卫生部和社会保健部、英国国际发展部、全球挑战研究基金、英国医学研究理事会、惠康信托基金会。
N Engl J Med. 2020-2-20
PLOS Glob Public Health. 2022-9-23
Ethn Dis. 2022-10-20
N Engl J Med. 2020-2-20